Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:27:26.477Z.
Calculation as of: 2026-10-06T20:27:26.477Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 733e4da94f9494cd21c7af02f5120fd8528014c079e3dffba0957966aae51245
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$22.00M
EBITDA Yield
N/A
TTM Avg
24.06%
3Y Avg
27.42%
5Y Avg
27.42%
Market Cap
$18.65M
EBITDA Yield
N/A
TTM Avg
4.87%
3Y Avg
4.87%
5Y Avg
4.87%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NextCure, Inc. (NXTC) | $20.53M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | 24.06% | 27.42% | 27.42% |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A | 4.87% | 4.87% | 4.87% |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.68M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
